- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946224
Comparison of Breast Acoustic CT and Automated Breast Ultrasound in Women With Unilateral Untreated Breast Cancer
Comparison of the Diagnostic Accuracy of Bilateral Whole Breast Ultrasound Using QT Imaging and Invenia Automated Breast Ultrasound (ABUS) [GE Healthcare] in Women With Unilateral Untreated Current Breast Cancer.
This study addresses an unmet need to improve the diagnostic accuracy of: 1. supplemental breast cancer screening with whole breast US and 2. the evaluation of disease extent in women with newly diagnosed breast cancer.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: David Marcellus
- Phone Number: 650-723-4547
- Email: dmarcel2@stanford.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University
-
Contact:
- David Marcellus
- Phone Number: 650-723-4547
- Email: dmarcel2@stanford.edu
-
Principal Investigator:
- Steven P Poplack, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Unilateral untreated breast cancer evaluated by breast MRI
- Participants' age range ≥18 years old
- Ability to understand and the willingness to provide written informed consent.
- Female gender
- Dense Breast composition
- Breast MRI available for reference comparison
- Able to undergo QT and ABUS imaging prior to definitive surgery or neoadjuvant therapy.
Exclusion Criteria:
- Prior mastectomy
- Bilateral breast cancer
- Concurrent use of investigational agents
- Active breast infection, open wound, or skin condition involving the breast that would interfere with imaging.
- Breast size or body habitus incompatible with QT or ABUS image acquisition. i. Breasts with cup size A through DDD. Up to 400lbs of patient weight is supported.
- Non-dense breast composition
- Pregnant
- Breast feeding
- Receipt of neoadjuvant chemotherapy, endocrine therapy, or radiation therapy before QT/ABUS imaging
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: QTI Breast Acoustic CT™ Scanner [QT Imaging] (QT), and Automated Breast Ultrasound (ABUS)
Each participant will undergo one (1) imaging examination using the investigational QT Scanner and one (1) imaging examination using the FDA-cleared Invenia™ Automated Breast Ultrasound System (ABUS). |
QT: The scanner is an FDA-cleared imaging technology that uses transmission ultrasound to generate quantitative maps of breast tissue properties (e.g., speed of sound, absorption) as well as provides reflection ultrasound images. It is a non-invasive, non-ionizing imaging modality and does not involve administration of a drug or biologic. Each participant will undergo one (1) imaging examination using the QT Scanner for comparison with images obtained using automated breast ultrasound (ABUS) ABUS is FDA-approved for both supplemental breast cancer screening in women with radiographically dense breast tissue, and for diagnostic breast ultrasound imaging. Each participant will undergo one ABUS imaging examination for comparison with images obtained using the investigational QT Scanner. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Additional Breast Cancer Lesions Detected
Time Frame: Baseline
|
The number of additional contralateral and ipsilateral breast cancer lesions detected using the QT scanner and ABUS as reported by study radiologists in women with dense breast tissue and newly diagnosed unilateral breast cancer. |
Baseline
|
|
BI-RADS Assessment
Time Frame: Baseline
|
Radiologists' diagnostic assessment of contralateral and ipsilateral breast cancer lesions identified using the QT Scanner and ABUS, as measured using the Breast Imaging Reporting and Data System (BI-RADS) classification categories. |
Baseline
|
|
Numerical Likelihood of Malignancy
Time Frame: Baseline
|
Radiologists will assess the likelihood of malignancy for contralateral and ipsilateral breast cancer lesions detected by QT Scanner and ABUS. Diagnostic confidence will be measured using the numerical likelihood-of-malignancy estimates assigned to identified lesions. |
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Steven P Poplack, Stanford University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-89405
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.